KFDA criticized for anti-obesity medicine license
Published: 2006-10-25 07:00:00
Updated: 2006-10-25 07:00:00
A lawmaker took issue with the Korea Food and Drug Administration's license withdrawal of Hanmi Pharm's anti-obesity drug Slimmer in the annual parliamentary audit on October 23, criticizing the health regulator's lack of equity in the procedures of drug approval.
Slimmer was a modified salt o...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
